Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01463046 · ClinicalTrials.gov registry record · Phase 1
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT01463046 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 29 participants.
The verdict
NCT01463046, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to see if Panobinostat is safe to give to patients and to determine the best dose to give in combination with standard cytarabine and daunorubicin chemotherapy.
Interventions
- DRUG Cytarabine
- DRUG Daunorubicin
- DRUG Panobinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2012-01 |
| Est. Completion | 2018-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01463046
The ClinicalTrials.gov registry entry for NCT01463046 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cytarabine is the first listed.
NCT01463046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01463046 about?
NCT01463046 is a clinical study titled "Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome". The purpose of this study is to see if Panobinostat is safe to give to patients and to determine the best dose to give in combination with standard cytarabine and daunorubicin chemotherapy.
What is the current status of trial NCT01463046?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2012-01. Estimated completion is 2018-12.
What interventions are being tested in trial NCT01463046?
The interventions under investigation include: Cytarabine (DRUG), Daunorubicin (DRUG), Panobinostat (DRUG).
Who is sponsoring clinical trial NCT01463046?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.